Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection

Dimier‐Poisson, Isabelle; Carpentier, Rodolphe; N'Guyen, Thi Thanh Loi; Dahmani, Fatima Zohra; Ducournau, Céline; Betbeder, Didier

doi:10.1016/j.biomaterials.2015.01.056

Cited by 57 publications

(58 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NPL are porous nanoparticles composed of reticulated cationic maltodextrin and filled with anionic phospholipids [5]. They have already shown great potential for mucosal vaccine applications, especially by the nasal route [4,6,8]. NPL can be loaded with large amounts of proteins or antigens [5,13] and act as an efficient delivery system.…”

Section: Discussionmentioning

confidence: 99%

“…NPL Synthesis and Characterization. NPL were prepared as described previously [6]. Briefly, maltodextrin (Roquette, France) was dissolved in 2 N sodium hydroxide with magnetic stirring at room temperature.…”

Section: Methodsmentioning

confidence: 99%

“…Samples were prepared by placing 5 μL (5 mg/mL) of NPL on 300 mesh ultrathin carbon film copper grids (Cu300-HD from Pacific Grid-Tech, San Francisco, USA). After removal of the excess water using a filter paper, the TEM grids were air-dried at room temperature for 10 minutes prior to analysis [6].…”

Section: Methodsmentioning

confidence: 99%

“…NPL are made of reticulated and positively charged (with trimethyl ammonium grafting) maltodextrin, an alpha(1,4)-glucose polymer, filled with an anionic phospholipid core [5]. NPL are porous, and their cationic charge is equally distributed in the material, not merely at the surface; incorporating anionic phospholipids in their core makes NPL zwitterionic [5,6]. They retain their colloidal stability in biological fluids, behave as a "stealth" nanoparticle [5], and can associate a large quantity (100% w/ w) [5] of a wide variety of antigens (e.g., more than 2000 different proteins in a complex mixture of a pathogen lysate) [6,7].…”

Section: Introductionmentioning

confidence: 99%

“…These NPL nanoparticles have already been successfully developed in our laboratory for toxoplasmosis vaccination via the nasal route [6]. The NPL-based toxoplasmosis vaccine exhibited a complete protection against the parasitic infection in both chronic and congenital diseases owing to a mixed Th1/Th17 protective immune response [6,8]. The vaccine formulation consisted of a total extract of the parasite associated with NPL.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Porous Maltodextrin-Based Nanoparticles: A Safe Delivery System for Nasal Vaccines

Carpentier

Platel

Salah

et al. 2018

Journal of Nanomaterials

Self Cite

View full text Add to dashboard Cite

Vaccination faces limitations, and delivery systems additionally appear to have potential as tools to trigger protective immune responses against diseases. The nanoparticles studied are cationic maltodextrin-based nanoparticles with an anionic phospholipid core (NPL); they are a promising antigen delivery system, and their efficacy as drug vectors against complex diseases such as toxoplasmosis has already been demonstrated. Cationic compounds are generally described as toxic; therefore, it is of interest to evaluate the behavior of these NPL in vitro and in vivo. Here, we studied the in vitro toxicity (cytotoxicity and ROS induction in intestinal and airway epithelial cell lines) and the in vivo tolerability and genotoxicity of these nanoparticles administered by the nasal route to a rodent model. In vitro, these NPL were not cytotoxic and did not induce any ROS production. In vivo, even at very large doses (1000 times the expected human dose), no adverse effect and no genotoxicity were observed in lungs, stomach, colon, or liver. This study shows that these NPL can be safely used.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Porous Maltodextrin-Based Nanoparticles: A Safe Delivery System for Nasal Vaccines

Carpentier

Platel

Salah

et al. 2018

Journal of Nanomaterials

Self Cite

View full text Add to dashboard Cite

show abstract

A potential cure for tumor‐associated immunosuppression by Toxoplasma gondii

Lotfalizadeh,

Sadr,

Morovati

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

BackgroundRecently, immunotherapy has become very hopeful for cancer therapy. Cancer treatment through immunotherapy has excellent specificity and less toxicity than conventional chemoradiotherapy. Pathogens have been used in cancer immunotherapy for a long time. The current study aims to evaluate the possibility of Toxoplasma gondii (T. gondii) as a probable treatment for cancers such as melanoma, breast, ovarian, lung, and pancreatic cancer.Recent findingsNonreplicating type I uracil auxotrophic mutants of T. gondii can stimulate immune responses against tumors by reverse immunosuppression at the cellular level. T. gondii can be utilized to research T helper 1 (Th1) cell immunity in intracellular infections. Avirulent T. gondii uracil auxotroph vaccine can change the tumor's immunosuppression and improve the production of type 1 helper cell cytokines, i.e., Interferon‐gamma (IFN‐γ) and Interleukin‐12 (IL‐12) and activate tumor‐related Cluster of Differentiation 8 (CD8+) T cells to identify and destroy cancer cells. The T. gondii profilin protein, along with T. gondii secreted proteins, have been found to exhibit promising properties in the treatment of various cancers. These proteins are being studied for their potential to inhibit tumor growth and enhance the effectiveness of cancer therapies. Their unique mechanisms of action make them valuable candidates for targeted interventions in ovarian cancer, breast cancer, pancreatic cancer, melanoma, and lung cancer treatments.ConclusionIn summary, the study underscores the significant potential of harnessing T. gondii, including its diverse array of proteins and antigens, particularly in its avirulent form, as a groundbreaking approach in cancer immunotherapy.

show abstract

Application of Nanotherapeutics for Combating Human Protozoan Parasitic Infections

Mehta

Sengupta

2021

Emerging Trends in Nanomedicine

View full text Add to dashboard Cite

Porous nanoparticles as delivery system of complex antigens for an effective vaccine against acute and chronic Toxoplasma gondii infection

Cited by 57 publications

References 39 publications

Porous Maltodextrin-Based Nanoparticles: A Safe Delivery System for Nasal Vaccines

Porous Maltodextrin-Based Nanoparticles: A Safe Delivery System for Nasal Vaccines

A potential cure for tumor‐associated immunosuppression by Toxoplasma gondii

Application of Nanotherapeutics for Combating Human Protozoan Parasitic Infections

Contact Info

Product

Resources

About